In addition, immunotherapies that aim to enhance MoMF levels and/or reparative activity are already being clinically pursued (58, 59) and could have a synergistic effect with the anti-LOXL2 mAb presented here on the recovery process from liver fibrosis. The gene discussed is LOXL2; the disease is Hepatic fibrosis.